| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | NEUTRAL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.60▼ | 6.61▼ | 6.61▼ | 6.33▲ | 6.70▼ |
| MA10 | 6.63▼ | 6.59▼ | 6.54▼ | 6.32▲ | 6.68▼ |
| MA20 | 6.58▼ | 6.43▲ | 6.35▲ | 6.73▼ | 6.99▼ |
| MA50 | 6.28▲ | 6.21▲ | 6.32▲ | 6.64▼ | 7.66▼ |
| MA100 | 6.22▲ | 6.52▼ | 6.76▼ | 7.08▼ | N/A |
| MA200 | 6.55▼ | 6.96▼ | 6.76▼ | 7.58▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.029▼ | 0.007▲ | 0.037▲ | -0.028▼ | -0.024▼ |
| RSI | 50.380▲ | 55.187▲ | 54.943▲ | 47.455▼ | 45.382▼ |
| STOCH | 35.076 | 61.141 | 73.893 | 40.522 | 47.283 |
| WILL %R | -100.000▼ | -61.111 | -31.884 | -50.003 | -69.459 |
| CCI | -207.195▼ | -16.810 | 26.483 | 26.161 | -51.964 |
|
Tuesday, January 06, 2026 06:52 AM
The clinical-stage biopharmaceutical company announced that its Phase 1 trial showed significant responses in difficult-to-treat pediatric cancers, including two Complete Metabolic Responses in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 07/01/26 | 6.875 | 6.885 | 6.50 | 6.50 | 43,333 |
| 06/01/26 | 6.63 | 6.83 | 6.42 | 6.66 | 94,620 |
| 05/01/26 | 6.26 | 6.445 | 6.03 | 6.34 | 326,101 |
| 02/01/26 | 6.6275 | 6.6275 | 5.78 | 6.03 | 59,506 |
| 31/12/25 | 6.03 | 6.26 | 5.7501 | 6.12 | 51,639 |
| 30/12/25 | 5.89 | 6.24 | 5.88 | 6.02 | 57,203 |
| 29/12/25 | 6.47 | 6.47 | 5.81 | 5.86 | 97,693 |
| 26/12/25 | 6.3427 | 6.645 | 6.3427 | 6.465 | 13,559 |
| 24/12/25 | 6.53 | 6.72 | 6.39 | 6.56 | 57,944 |
| 23/12/25 | 6.89 | 6.89 | 6.51 | 6.61 | 19,977 |
|
|
||||
|
|
||||
|
|